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Potential Cost Avoidance of Adverse Drug Reactions 
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ABSTRACT: Pharmacists’ intervention in hospital setting is very beneficial both in patients’ clinical out-
come and economic aspect, in terms of cost avoidance due to adverse drug reactions. This study was con-
ducted to calculate cost avoidance of adverse drug reactions (ADR) prevention in outpatient pharmacy 
department in Ramathibodi Hospital Thailand. A retrospective database review of hospital pharmacy 
interventions preventing adverse drug reaction was conducted at second floor pharmacy unit, Somdech-
PhraDebaratana Medical Center, Ramathibodi hospital between 1 July 2013 and 31 December 2013. Po-
tential cost avoidance of ADR was calculated using diagnosis-related groups (DRG’s) data. Results showed 
that the detection of ADR was 0.239%. The most frequent ADR came from Penicillin group was accounted 
for 32.4% of total case. The estimated cost avoidance generated during July-December 2013 was Thai 
Baht (THB) 592,320 to THB 1,257,428 (USD 19,278 to USD 40,925, value 2013). It can be concluded 
that hospital pharmacists positively impacted on economic benefit of patients by providing ADR detec-
tion. More complete data are needed to get a better results of a real cost avoidance of ADR prevention.
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1. Introduction
Definition of adverse drug reaction (ADR) 
according to world health organization (WHO) is “a 
response to a drug that is noxious and unintended 
and occurs at doses normally used in man for the 
prophylaxis, diagnosis or therapy of disease, or for 
modification of physiological function”. The latest 
definition of ADR from Edwards and Aronson is 
“an appreciably harmful or unpleasant reaction, resulting from an intervention related to the use of a medicinal product, which predicts hazard from future administration and warrants prevention 
or specific treatment, or alteration of the dosage 
regimen, or withdrawal of the product” [1]. 
The incidences of serious ADR ranged from 
6.7%-26.1% [2-7]. A meta-analysis study from 
Lazarou et al. reported the overall incidence of 
serious ADR of hospitalized patients was 6.7%. 
This was found to be extremely high and more 
dangerous than in outpatients [2]. A study from Bennett et al. showed the incidence was 7.2% 
(5.9% of 85 surgical patients and 9.0% of 67 
medical patients) [3]. Another study showed that 
the overall incidence of ADRs among hospitalized 
children was 9.53% and was a significant public 
health issue [4]. Another issue is 3% of the 
admissions were related to ADRs. In addition, 
6.6% of hospitalized patients had significant 
ADRs. Between 5 and 9% of hospital costs were 
related to ADRs. Point prevalence of ADRs at 
admission was 3%, incidence rate in hospital was 
5.6/1000 patient-days [6]. The incidence of fatal adverse drug reactions in hospitalized patients 
has been estimated to be approximately 5% and 
3% of it were suspected to have died from fatal 
ADRs [7]. The biggest number incidence of ADR 
was presented by Lagnaoui et al. They found 
26.1% ADRs occurred of all admissions [5].
Adverse drug reactions known as cause of 
highly cost of medical expenditures. A study from 
South India showed the total cost incurred in 
managing all the reported ADRs was Rs 76 564 
(US$ 1595) with an average cost of Rs 690 (US$ 
15) per ADR [8]. Increased ADR-induced costs 
from hospitalized patients in a cardiovascular 
hospital in France costs Euro 4150 per ADR [9]. It 
means if ADR can be prevented, it can save a huge 
amount of money. A study from Goettler et al. 
showed cost of admission due to ADR was 1050 
million DM per year in Germany. Preventability of 
ADR from previous ADR revealed about 30% of all 
ADRs to be preventable. With regard to Germany 
this means that 350 million DM per year could 
be saved by preventing adverse drug reactions 
[10]. The cost of ADRs leading to hospitalization 
in France by a study from Lagnaoui et al. was 
estimated at Euro 11,357 per hospital bed per 
year. Eighty percent of ADRs could be considered 
preventable [5].
One of roles of hospital pharmacist is to prevent 
adverse drug reactions (ADR) through clinical 
pharmacy services. One study from Kucukarslan 
et al. showed the rate of preventable adverse drug 
events (ADE) by pharmacist participation with the 
medical rounding team was reduced significantly 
by about 78%  [11]. Another study from Murray et 
al. was shown pharmacist intervention can lower 
risk of ADE and medication errors in outpatients 
with cardiovascular disease [12].
Economic benefit on this service was shown 
in some studies. A study showed actual and 
potential cost avoidance totaled $54,730.56. The pharmacist provided value-added services and contributed to decreased costs associated 
with care [13]. Another study from Lee  showed the overall mean cost avoidance per 
recommendation of clinical pharmacy services 
at a Veteran Affairs medical center was $700, 
and the mean total cost avoidance for all 600 
recommendations was $420,155. Pharmacist recommendations improved clinical outcomes 
and saved money [14]. Study from Westerlund 
et al. demonstrates that community pharmacy 
interventions in patient DRPs are most likely to lead to favourable clinical and economic 
outcomes. The potential societal cost savings 
extrapolated to Sweden at the national level were 
estimated at € 358 million [15]. Review study 
from Lada and Delgado showed that most studies 
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reported positive financial benefits of the clinical 
pharmacy service evaluated. In 16 studies, a 
benefit:cost ratio was reported by the authors 
or was able to be calculated by the reviewers 
(ranged from 1.7:1-17.0:1, median 4.68:1) [16].
Even though many studies reported 
economic benefit of hospital pharmacy services, 
this kind of benefit of cost avoidance where 
specifically conducted in outpatient department 
Ramathibodi Hospital Thailand has not been 
proven. Therefore, the objective of this study was 
to calculate cost avoidance of ADR prevention in 




This study was a retrospective, based 
on database review of hospital pharmacy 
interventions preventing ADR conducted at 
second floor pharmacy unit, Somdech Phra 
Debaratana Medical Center (SDMC), Ramathibodi 
hospital Thailand between July 1, 2013 and 
December 31, 2013.
2.2. Setting and patient population
This study was conducted at the second-floor 
pharmacy outpatient department (OPD) unit 
of Somdech Phra Debaratana Medical Center 
(SDMC), the Faculty of Medicine Ramathibodi 
Hospital Thailand, a university hospital of 
Mahidol University, which has three principal 
buildings to serve more than 5,000 out-patients 
per day. Somdech Phra Debaratana Building 
(royally opened by Somdech Phra Debaratana 
on August 14, 2011) is the largest and newest 
building, serves as the most excellent service 
complex for thousands of out-patients of all types 
of healthcare coverage per day.
This study targeted toward outpatients in 
the second-floor pharmacy unit, Somdech Phra 
Debaratana Medical Center which composed of 5 
clinics as follows 1) Surgery OPD; 2) Orthopedics 
OPD; 3) Eye, Ear, Nose, and Throat (EENT) OPD; 
4) Dermatology OPD; and 5) Pain clinic. 
2.3. Data collection
The data were collected by pharmacists 
from spontaneous DRPs report at hospital 
which focused on adverse drug prevention. The information collected were about the adverse drug reactions occurred, and activities performed 
by pharmacists and physicians. Patient who has been suspected drug related 
problems (DRPs), following classification by van 
den Bemt, would be notified to the physician by 
blue paper and confirmed the order correctly 
before patient received the medicine [17]. When 
the suspected DRPs was notified or detected from the process, pharmacist would input the 
detail in Microsoft Excel program. All activities 
regarding entering interventions were voluntary. 
We defined potential cost avoidance as the cost 
of treatment that may have been incurred if an 
intervention had not occurred.
2.4. Data analysis
Data were analyzed by using Excel program 
and the findings were presented in 2 areas:
1) Total number of ADRs preventing by
pharmacist. We simply calculated the 
number of ADRs detection by pharmacist.
2) The cost of treating ADR complications 
if pharmacists could not detect it. Cost included 
in this study was direct medical cost. ADRs  from 
each drug were derived from Spontaneous ADR 
report by Thai Food and Drug Administration 
(Thai FDA) [18]. We estimate potential ADRs that 
may have occurred by range it from mild to severe 
ADR from that report. Mild ADR was defined as 
ADR that cause the least impact to patient, e.g. 
rash and pruritus; and severe ADR was defined 
as ADR that cause harm to patient, e.g. Stevens-
Johnsons syndrome and erythema multiforme. 
Mild and severe ADR were also known from the 
relative weight of the severity of ADR, range 
from 0 to 1. Then, we determined how much 
potential cost avoidance by using cost of each 
treatment from diagnosis-related group (DRG’s) 
data. In DRG, one relative weight was accounted 
THB 9,600. To estimate the uncertainty of ADRs 
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that may have occurred; we conducted a simple 
sensitivity analysis to range the calculation 
from mild ADR case to severe ADR case. Total cost avoidance would be the result 
of the number of detection of ADR multiply by 
relative weight of severity of ADR. All costs were 
presented in Thai Baht year 2013 (USD 1 = THB 
30.725, value 2013).
3. Result
During 1 July-31 December 2013, we found 
223 events of ADR that could be prevented by 
pharmacist of 93,303 prescriptions. The detection 
of ADR was 0.239%. Total number of pharmacist 
was 10, divided into 7 full timer pharmacists 
(08.30-16.30) and 3 part timer pharmacists 
(10.00-15.00). Average cases of ADR every month 
was 36.8 cases and one pharmacist could prevent 
22 cases in average for 6 months and saved THB 
92,487.4.
Total cost avoidance of 223 events of ADR 
prevention was THB 592,320 in mild case and 
THB 1,257,428 in the worst case (Table 1). 
Average cost per incidence was THB 2,656.14 in 
mild case and THB 5,638.9 in severe case. Most 
of drugs which ADR were prevented in OPD 
Ramathibodi Hospital were antibiotics (Penicillin, 
Cephalosporin, Quinolone, and Sulfa group) and 
analgesic (Paracetamol, Ibuprofen, Meloxicam, 
Piroxicam, Naproxen). The other drugs were 
Coxib, muscle relaxant, and GABA. Penicillin group was accounted as the most frequent drug with 
total 72 cases. The incidence of Penicillin group 
was 32.58% of total case. Mild ADR varied from rash, to maculopapular (MP)-rash, angioedema, 
pruritus, and urticaria. Severe ADR also varied 
from Stevens-Johnsons syndrome, to erythema 
multiforme, dyspnea, and palpitation.The bigger proportion of cost avoidance came 
from Amoxicillin (N=22) that was counted THB 
135,759 in the worst case and THB 51,617 in 
mild case, followed by Amoxicillin & clavulanate 
and Penicillin V each was accounted for THB 
117,247 in the worst case and THB 44,579 in mild 
case. The trend of ADR prevention in 2013 was 
decreasing in the first four months but increasing 
afterwards (Figure 1). The least cases were 
reported in October (N=17 cases) and the most 
cases were reported in December (N=65 cases). 
4. Discussion
Hospital pharmacists’ intervention in 
outpatient department Ramathibodi Hospital had a positive impact on cost avoidance for 
preventing ADR events. They performed screening on the prescriptions and corrected the 
prescribing errors. We found 223 cases of ADR 
that pharmacists could prevent during 1 July-31 
December 2013, with a range of cost avoidance 
from THB 592,320 to THB 1,257,428. One 
pharmacist could save THB 92,487.4in six months. 
Average cost per incidence was THB 2,656.14 in 
mild case and THB 5,638.9 in severe case. This cost seemed not so high when we compare to 
other study from Lada and Delgado [19] which 
was performed documentation of pharmacists’ 
interventions in an emergency department and 
associated cost avoidance, they found between 
1 September 2003 and 31 December 2003 cost 
avoidance during the study was determined to 
be $1,029,776. Another findings from Galt [20] showed actual and potential cost avoidance in a Veterans Affairs Medical Center totaled 
Figure 1. Number of ADR in each month
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$54,730.56. The differences of our result with the 
above study might be caused of the differences in the number patients and differences in presenting 
total cost avoidance. In Lada and Delgado’s study, 
they extrapolated the cost into one year [19]. The pharmacist provided value-added services and contributed to decreased costs associated with 
care. Similar study from Woolley [21] evaluated 
potential cost avoidance of pharmacy students’ intervention estimated potential total cost 
avoidance of $908,800. 
These findings may be caused of under 
reported data. The data was collected only from 
normal clinic which open from 08.30-16.30 only 
on the second floor of Somdech Phra Debaratana 
Medical Center building. The data from special 
clinic (16.30-21.00) and from other outpatient 
departments were not included in this study. The 
number of detection of ADR was 0.239%. This was quite low if we compare to other studies 
where the incidence of serious ADR ranged from 
6.7%-26.1% [2-7]. In our knowledge, there was 
no study exploring potential cost avoidance by 
pharmacist in outpatient department. Most study 
were performed in hospitalized patients [6, 9, 13], 
showed the relationship of ADR and admission.
Our study had several limitations. Firstly, we 
collected data from some outpatient clinics only, 
so that generalizability to the other outpatient 
department should be made with cautions. 
Secondly, the limitation from the data itself. Due 
to retrospective way of this study, some data were 
loss (e.g. patients’ name and hospital number) and 
some were incomplete. We suggested to the next 
study to perform study in prospective way or in 
experimental design to compare usual activities 
and pharmacists’ interventions activities, such as dose adjustment, drug information to patient, 
patient education, etc. 
The most frequent drug we found of ADR 
was in Penicillin group, such as Amoxicillin and 
Amoxicillin & clavulanate. This might due to the 
number of usage of antibiotics in the hospital. Our 
findings showed that many events of ADR came 
from cross-reactivity of drugs in similar structure, 
such as beta-lactam antibiotics [22]. Physicians, 
the one who wrote prescriptions mostly did 
not aware of this kind of issue. Moreover, they 
were still prescribing in manual way (writing 
prescriptions on a paper). Pharmacist was also 
the one who responsible to key in information 
of drug allergy. Some data of allergy might be loss because of problem in connection between 
physician and pharmacist. Our suggestions were to implement electronic prescribing and to 
improve database systems. Information of drug 
allergy would be contained with possibility of 
cross-reactivity among drugs.
5. Conclusion
Hospital pharmacists positively impacted 
on economic benefit of patients by providing 
ADR detection. The estimated cost avoidance 
generated during 1 July-31 December 2013 was 
THB 592,320-THB 1,257,428 (USD 19,278-USD 
40,925). More complete data needed to get a 
better results of real cost avoidance of ADR.
Acknowledgements
The authors are thankful to Pharmacy Unit 
Ramathibodi Hospital for providing data to our 
work. There is no conflict of interest in our study.
References 
1. Edwards IR, Aronson JK. Adverse 
drug reactions: definitions, diagnosis, 
and management. The Lancet. 
2000;356(9237):1255-9.
2. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized 
patients: A meta-analysis of prospective 
studies. JAMA. 1998;279(15):1200-5.
3. Bennett B, Lipman A. Comparative study 
of prospective surveillance and voluntary reporting in determining the incidence of 
adverse drug reactions. American Journal of 
Health-System Pharmacy. 1977;34(9):931-6.
4. Impicciatore P, Choonara I, Clarkson A, 
Provasi D, Pandolfini C, Bonati M. Incidence 
Media Pharmaceutica Indonesiana ¿ Vol. 1 No. 3 ¿ Juni 2017 143
Nia Kurnia Sholihat, Wasin Chimsawat
of adverse drug reactions in paediatric in/
out-patients: a systematic review and meta-
analysis of prospective studies. British Journal 
of Clinical Pharmacology. 2001;52(1):77-83.
5. Lagnaoui R, Moore N, Fach J, Longy-Boursier 
M, Bégaud B. Adverse drug reactions in a 
department of systemic diseases-oriented internal medicine: prevalence, incidence, 
direct costs and avoidability. E J Clin 
Pharmacol. 2000;56(2):181-6.
6. Moore N, Lecointre D, Noblet C, Mabille M. 
Frequency and cost of serious adverse drug 
reactions in a department of general medicine. 
British Journal of Clinical Pharmacology. 
1998;45(3):301-8.
7. Wester K, Jönsson AK, Spigset O, Druid H, Hägg 
S. Incidence of fatal adverse drug reactions: 
a population based study. British Journal of 
Clinical Pharmacology. 2008;65(4):573-9.
8. Ramesh M, Pandit J, Parthasarathi 
G. Adverse drug reactions in a South 
Indian hospital—their severity and cost 
involved. Pharmacoepidemiol Drug Saf. 
2003;12(8):687-92.
9. Bordet R, Gautier S, Le Louet H, Dupuis B, 
Caron J. Analysis of the direct cost of adverse 
drug reactions in hospitalised patients. E J 
Clin Pharmacol. 2001;56(12):935-41.
10. Goettler M, Schneeweiss S, Hasford J. Adverse 
drug reaction monitoring--cost and benefit 
considerations. Part II: cost and preventability of adverse drug reactions leading to hospital 
admission. Pharmacoepidemiol Drug Saf. 
1997;6 Suppl 3:S79-90. Epub 2004/04/10.
11. Kucukarslan SN, Peters M, Mlynarek M, 
Nafziger DA. PHarmacists on rounding teams reduce preventable adverse drug events in 
hospital general medicine units. Archives of 
Internal Medicine. 2003;163(17):2014-8.
12. Murray MD, Ritchey ME, Wu J, Tu W. EFfect of a pharmacist on adverse drug events and medication errors in outpatients with 
cardiovascular disease. Archives of Internal 
Medicine. 2009;169(8):757-63.
13. McMullin S, Hennenfent JA, Ritchie DJ, et al. 
A prospective, randomized trial to assess the cost impact of pharmacist-initiated 
interventions. Archives  of Internal Medicine. 
1999;159(19):2306-9.
14. Lee AJ, Boro MS, Knapp KK, Meier JL, Korman 
NE. Clinical and economic outcomes of pharmacist recommendations in a Veterans 
Affairs medical center. American Journal of 
Health-System Pharmacy. 2002;59(21):2070-
7.
15. Westerlund T, Marklund B. Assessment of the 
clinical and economic outcomes of pharmacy 
interventions in drug-related problems. 
Journal of Clinical Pharmacy and Therapeutics. 
2009;34(3):319-27.
16. Schumock GT, Butler MG, Meek PD, Vermeulen 
LC, Arondekar BV, Bauman JL, et al. Evidence 
of the Economic Benefit of Clinical Pharmacy 
Services: 1996–2000. Pharmacotherapy: The 
Journal of Human Pharmacology and Drug 
Therapy. 2003;23(1):113-32.
17. van den Bemt P. Drug related problems: 
definitions and classification. EJHP Practice. 
2005;11:16.
18. Center HPV. Spontaneous ADR report by Thai 
FDA. 2014 [14 January 2014]; Available from: 
http://thaihpvc.fda.moph.go.th/thaihvc/
Public/Webpage/main.jsp.
19. Lada P, Delgado JG. Documentation of 
pharmacists' interventions in an emergency 
department and associated cost avoidance. 
American Journal of Health-System Pharmacy. 
2007;64(1):63-8.
20. Galt KA. Cost Avoidance, Acceptance, and 
Outcomes Associated with a Pharmacotherapy Consult Clinic in a Veterans Affairs Medical 
Center. Pharmacotherapy: The Journal of 
Human Pharmacology and Drug Therapy. 
1998;18(5):1103-11.
21. Woolley AB, Berds CAt, Edwards RA, 
Copeland D, DiVall MV. Potential cost 
avoidance of pharmacy students' patient 
care activities during advanced pharmacy 
practice experiences. Am J Pharm Educ. 
2013;77(8):164. Epub 2013/10/26.
Media Pharmaceutica Indonesiana ¿ Vol. 1 No. 3 ¿ Juni 2017144
Potential Cost Avoidance of Adverse Drug Reactions Prevention in Outpatient Pharmacy Department Ramathibodi Hospital Thailand
22. James CW, Gurk-Turner C. Cross-reactivity of 
beta-lactam antibiotics. Proc (Bayl Univ Med 
Cent). 2001;14(1):106-7. Epub 2005/12/22.
